Research progress of tertiary lymphoid structure in prognosis and immunotherapy of esophageal squamous cell carcinoma
- VernacularTitle:三级淋巴结构在食管鳞状细胞癌预后及免疫治疗中的研究进展
- Author:
Zhenyi NIU
1
;
Runsen JIN
1
;
Kepeng YAN
1
;
Yan ZHANG
2
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
2. Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal squamous cell carcinoma;
tertiary lymphoid structure;
immunotherapy;
tumor immune microenvironment;
immune checkpoint inhibitors;
antitumor immune response;
prognosis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(03):468-474
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal squamous cell carcinoma is the main histological type of esophageal cancer in China, which seriously threatens the health of people. The application of immunotherapy, mainly immune checkpoint inhibitors, has greatly improved the prognosis of patients with esophageal squamous cell carcinoma, but the efficacy of treatment is still limited. Tertiary lymphoid structure (TLS) is an ectopic organized lymphoid structure that accumulates in non-lymphoid organs. Previous studies have found that TLS in esophageal squamous cell carcinoma is associated with better patient outcomes and enhanced immunotherapy efficacy. Based on current researches about TLS in esophageal squamous cell carcinoma, this paper reviews the relationship between TLS and the prognosis and immunotherapy of patients. We hope to provide reference for the precise immunotherapy of esophageal squamous cell carcinoma.
